News

Innovative drug delivery platform shows significant vision improvement and IOP reduction in glaucoma patients, promising a new treatment paradigm.

Jeffrey Levenson, MD, discusses the sustained reduction of ocular inflammation and pain post ocular surgery with clobetasol propionate ophthalmic suspension.

Katherine Talcott, MD, discuss the impact of intravitreal injections on intraocular pressure, emphasizing monitoring and patient safety in treatment.

Young shared with his real-world experiences with etranacogene dezaparvovec gene therapy.

Christina Y. Weng, MD, breaks down emerging gene therapy programs poised to change how retina specialists treat chronic eye disease.

In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.

A systematic review suggests introducing denatured or baked egg under supervision could reduce the burden of strict allergen avoidance.

Norouzi reflects on significant advances in glomerular disease from Q1 and looks ahead to what the rest of 2025 may have to offer.

A major factor of type 2 diabetes mellitus, dyslipidemia can potentially be prevented by closely monitoring lipid profiles.

Parent company VivaVision plans to request a type C meeting with the US Food and Drug Administration.

These data point to the necessity of incorporating disease burden in patient interactions and decision making for those under the age of 18 years.

Prophylactic treatment with IV magnesium led to a lower risk of cisplatin-associated AKI in patients with cancer undergoing cisplatin chemotherapy.

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.

In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.

Real-world data show omalizumab, alone or with OIT, is effective and well-tolerated for IgE-mediated food allergy, with high response rates in adults.

Findings suggest frequent consumption of non-skimmed milk may heighten the risk of developing MAFLD.

Researchers indicated an association between the index and 365-day mortality.

In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.

These data highlight the risk level among certain patients with psoriasis of excessive sun exposure, associated commonly with tanning.

1 in 5 patients were incompletely screened for CFLD based on 2023 guidelines, with Hispanic ethnicity and public insurance linked to an increased risk.

The program can indicate the severity of nail psoriasis and allow practitioners to quickly and accurately diagnose patients.

In new preference research, the average participant with AA was willing to trade approximately 5 years of life to avoid impacts associated with 50–100% scalp hair loss.

In these findings, the FamilyPso tool was validated for assessing psoriasis burdens on family members in multiple countries.

Healthier hair and scalp according to Hair & Scalp CARE questionnaire responses was linked to lower levels of perceived stress and good sleep health.

An observational study has indicated a correlation between biologic medications and a lower risk of CVD: more research is needed to determine causality.

The findings may facilitate accurate diagnoses, which could help patients slow or stop permanent hair loss.